IP Library Granted Patent US 9,073,980
Granted Patent B2
US 9,073,980 · App. 13/254,825 · Granted Jul 7, 2015

Tumor selective E1a and E1b mutants

Inventors: Tony Reid (San Diego, CA); Farah Hedjran (San Diego, CA); Shantanu Kumar (San Diego, CA)
Assignee: The Regents of the University of California
C07K14/005A61K48/00C12N7/00C12N15/86C12N2710/10321C12N2710/10322C12N2710/10332C12N2710/10343C12N2830/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,073,980
App. No.
13/254,825
Granted
Jul 7, 2015
Kind
B2
Abstract

Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.

Claims (15)

1. A recombinant adenovirus-comprising:

(i) a DNA sequence inserted into an E1b-19K insertion site, wherein the insertion site is located between the start site of E1b-19K and the start site of E1b-55K; and

(ii) a modified E1a regulatory sequence, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted.

2. The recombinant adenovirus of claim 1 , wherein the insertion site comprises a deletion of 202 base pairs following the start site of E1b-19K.

3. The recombinant adenovirus of any one of claims 1 or 2 , wherein the DNA sequence is a sequence encoding tumor necrosis factor, or a functional portion thereof.

4. The recombinant adenovirus of any one of claims 1 or 2 , wherein the DNA sequence is a sequence encoding kras, or a functional portion thereof.

5. The recombinant adenovirus of claim 1 , wherein at least one nucleotide in the range of −305 to −141 of said E1a regulatory sequence is retained.

6. The recombinant adenovirus of claim 1 , wherein at least one of Pea3 II, Pea3 III, Pea3 IV, and Pea3 V, or a functional portion thereof, is deleted.

7. The recombinant adenovirus of claim 1 , comprising the nucleic acid sequence of vector dl309-6, TAV-255, dl55, dl200, dl230, or dl200+230.

8. The recombinant adenovirus of claim 7 , comprising the nucleic acid sequence of vector TAV-255.

9. The recombinant adenovirus of claim 1 , wherein said recombinant virus selectively expresses an E1a isoform, wherein the sequence encoding the E1a isoform is operably linked to said modified E1a regulatory sequence.

10. The recombinant adenovirus of claim 9 , wherein the virus selectively expresses E1a-12S.

11. The recombinant adenovirus of claim 9 , wherein the virus selectively expresses E1a-13S.

12. The recombinant adenovirus of claim 1 , wherein said recombinant virus substantially excludes expression of an E1a isoform, wherein the sequence encoding the E1a isoform is operably linked to said modified E1a regulatory sequence.

13. The recombinant adenovirus of claim 12 , wherein the excluded E1a isoform is E1a-12S or E1a-13S.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2011
From: REID, TONY; HEDJRAN, FARAH; KUMAR, SHANTANU
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 027396/0583 →
Continuity (2)
Provisional Application 61156822 · Mar 2, 2009
Related Publication 20110318311A1 · Dec 29, 2011